Nat Commun :重大进展!中山大学蔡俊超/吴珏珩发现肺腺癌新的潜在治疗靶标

2020-10-22 枫叶 iNature

尽管AKT过度活化在肿瘤进展中很重要,但是各种AKT抑制剂的临床试验结果仍然不是最佳的,这表明需要进一步了解AKT驱动的肿瘤转移。

尽管AKT过度活化在肿瘤进展中很重要,但是各种AKT抑制剂的临床试验结果仍然不是最佳的,这表明需要进一步了解AKT驱动的肿瘤转移。

2020年10月12日,中山大学蔡俊超及吴珏珩共同通讯在Nature Communications 在线发表题为“AKT-induced lncRNA VAL promotes EMT-independent metastasis through diminishing Trim16-dependent Vimentin degradation”的研究论文,该研究基于由AKT诱导的长非编码RNA(lncRNA)分析,鉴定出由AKT / STAT3信号直接诱导的VAL(波形蛋白相关的lncRNA,LINC01546)起着有效的促转移分子的作用,并且对于主动AKT诱导的肺腺癌(LAD)的肿瘤浸润,转移和无神经耐受性至关重要。

有趣的是,与LAD细胞中活化的AKT相似,尽管VAL无法诱导上皮-间质转化(EMT),但VAL通过直接结合波形蛋白并竞争性地消除依赖Trim16的波形蛋白多泛素化和降解,发挥了强大的促侵袭和促转移作用。综上所述,该研究为lncRNA介导的AKT驱动的非EMT依赖性LAD转移机制提供了有趣的证明,并表明了靶向VAL或波形蛋白稳定性作为治疗方法的巨大潜力。

肺癌是最常见的癌症类型,也是全世界与癌症相关的死亡的主要原因。非小细胞肺癌(NSCLC)约占所有肺癌病例的85%,而肺腺癌(LAD)是一种主要的组织学类型,约占NSCLC病例的50%。据估计,近三分之二的NSCLC患者在初诊时显示出局部或远处转移的证据,中位生存期约为7个月,而只有1%的转移性NSCLC患者在诊断后可以生存5年以上。原发性肿瘤病灶中的NSCLC细胞通常扩散到淋巴结,对侧肺和远处的器官,如骨骼,大脑和肝脏。因此,重要的是更好地了解NSCLC转移的潜在机制,并确定转移性NSCLC的有效治疗靶标或预后生物标志物。

肿瘤的侵袭和转移涉及复杂的级联过程,包括获得侵袭和迁移能力,与原发肿瘤分离,循环流生存,外渗,粘连和在次级部位定植。重要的是上皮-间质转化(EMT)是转移级联过程中至关重要的第一步,其中上皮细胞失去极化,细胞间接触,并获得成纤维细胞样形态。进行EMT通常可使非转移性或低转移性肿瘤细胞具有高度侵袭性 。然而,在没有EMT激活的情况下,原发肿瘤的转移也经常发生。这些研究突出了这样一个事实,即肿瘤转移的潜在机制远比人们所了解的更为复杂。

AKT信号通路在癌细胞的几乎所有特征的发展中起着关键作用。AKT过度活化与临床分期以及患者预后不良之间的密切关系在包括NSCLC在内的各种类型的癌症中都有很好的记录。越来越多的证据揭示了AKT过度激活促进肿瘤侵袭和转移的各种机制。尽管活化的AKT在各种癌症中具有重要意义,并且在开发针对AKT的疗法方面付出了巨大的努力,但各种AKT抑制剂的临床试验结果仍然不理想。

长非编码RNA(lncRNA)是一类长于200个核苷酸的内源RNA,具有极低的蛋白质编码能力,已被证明基本上参与了各种基本的生物学事件和疾病。在分子水平上,lncRNA可以充当诱饵,与蛋白质和microRNA结合,或充当支架或引导物来调节蛋白质与蛋白质或蛋白质与DNA的相互作用,从而可以在表观遗传,转录,翻译,转录后和翻译后水平上调节基因表达。越来越多的证据表明,lncRNA在肿瘤的发生和发展中代表了一类独特的主调节因子。然而,大多数lncRNA在AKT驱动的肿瘤发展和进展中的作用仍不清楚。

在本研究中,在活化的过表达AKT的LAD细胞系中分析了lncRNA的表达,该细胞系具有与EMT过程无关的显着增强的转移能力,并鉴定了一种基因间的细胞质lncRNA VAL(LINC01546,ENSG00000228459),该蛋白是由AKT通过STAT3转录活性激活的并与疾病进展和LAD不良预后相关。该研究进一步证明,该lncRNA对于由AKT过度激活驱动的LAD转移至关重要。

有趣的是,尽管VAL无法诱导EMT,但VAL通过直接结合波形蛋白并通过其先前未建立的E3连接酶Trim16诱导竞争性降解波形蛋白降解而增强了LAD的侵袭和转移。这些结果应提供有关LAD转移过程的见识,以及LAD诊断和治疗的机会。

原始出处:

Han Tian, Rong Lian, Yun Li, et al.AKT-induced lncRNA VAL promotes EMT-independent metastasis through diminishing Trim16-dependent Vimentin degradation.Nat Commun. 2020 Oct 12;11(1):5127. doi: 10.1038/s41467-020-18929-0.

版权声明:
本网站所有内容来源注明为“梅斯医学”或“MedSci原创”的文字、图片和音视频资料,版权均属于梅斯医学所有。非经授权,任何媒体、网站或个人不得转载,授权转载时须注明来源为“梅斯医学”。其它来源的文章系转载文章,或“梅斯号”自媒体发布的文章,仅系出于传递更多信息之目的,本站仅负责审核内容合规,其内容不代表本站立场,本站不负责内容的准确性和版权。如果存在侵权、或不希望被转载的媒体或个人可与我们联系,我们将立即进行删除处理。
在此留言
评论区 (18)
#插入话题
  1. [GetPortalCommentsPageByObjectIdResponse(id=1884746, encodeId=4cb61884e46b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 21 22:50:21 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909463, encodeId=b17119094636b, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Mar 14 11:50:21 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956827, encodeId=a37495682ea4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/201a0bf1c8774775920c4db17c2a4ddb/0a8d2c62e4cb4d58b3ecbc9c2ed8b2f9.jpg, createdBy=62f95139558, createdName=1931, createdTime=Wed Apr 14 10:13:46 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087812, encodeId=edcf208e8123a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 18 12:50:21 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814540, encodeId=9f8118145402c, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Nov 25 12:50:21 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895031, encodeId=4dac89503195, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Wed Oct 28 11:45:03 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894218, encodeId=26f2894218d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:47:10 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894217, encodeId=b25a89421e0a, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:46:46 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352871, encodeId=c80713528e1dd, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555778, encodeId=e4691555e7825, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2021-09-21 liye789132251
  2. [GetPortalCommentsPageByObjectIdResponse(id=1884746, encodeId=4cb61884e46b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 21 22:50:21 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909463, encodeId=b17119094636b, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Mar 14 11:50:21 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956827, encodeId=a37495682ea4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/201a0bf1c8774775920c4db17c2a4ddb/0a8d2c62e4cb4d58b3ecbc9c2ed8b2f9.jpg, createdBy=62f95139558, createdName=1931, createdTime=Wed Apr 14 10:13:46 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087812, encodeId=edcf208e8123a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 18 12:50:21 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814540, encodeId=9f8118145402c, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Nov 25 12:50:21 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895031, encodeId=4dac89503195, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Wed Oct 28 11:45:03 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894218, encodeId=26f2894218d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:47:10 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894217, encodeId=b25a89421e0a, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:46:46 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352871, encodeId=c80713528e1dd, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555778, encodeId=e4691555e7825, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
  3. [GetPortalCommentsPageByObjectIdResponse(id=1884746, encodeId=4cb61884e46b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 21 22:50:21 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909463, encodeId=b17119094636b, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Mar 14 11:50:21 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956827, encodeId=a37495682ea4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/201a0bf1c8774775920c4db17c2a4ddb/0a8d2c62e4cb4d58b3ecbc9c2ed8b2f9.jpg, createdBy=62f95139558, createdName=1931, createdTime=Wed Apr 14 10:13:46 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087812, encodeId=edcf208e8123a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 18 12:50:21 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814540, encodeId=9f8118145402c, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Nov 25 12:50:21 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895031, encodeId=4dac89503195, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Wed Oct 28 11:45:03 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894218, encodeId=26f2894218d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:47:10 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894217, encodeId=b25a89421e0a, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:46:46 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352871, encodeId=c80713528e1dd, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555778, encodeId=e4691555e7825, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2021-04-14 1931

    学习

    0

  4. [GetPortalCommentsPageByObjectIdResponse(id=1884746, encodeId=4cb61884e46b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 21 22:50:21 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909463, encodeId=b17119094636b, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Mar 14 11:50:21 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956827, encodeId=a37495682ea4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/201a0bf1c8774775920c4db17c2a4ddb/0a8d2c62e4cb4d58b3ecbc9c2ed8b2f9.jpg, createdBy=62f95139558, createdName=1931, createdTime=Wed Apr 14 10:13:46 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087812, encodeId=edcf208e8123a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 18 12:50:21 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814540, encodeId=9f8118145402c, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Nov 25 12:50:21 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895031, encodeId=4dac89503195, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Wed Oct 28 11:45:03 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894218, encodeId=26f2894218d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:47:10 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894217, encodeId=b25a89421e0a, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:46:46 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352871, encodeId=c80713528e1dd, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555778, encodeId=e4691555e7825, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
  5. [GetPortalCommentsPageByObjectIdResponse(id=1884746, encodeId=4cb61884e46b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 21 22:50:21 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909463, encodeId=b17119094636b, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Mar 14 11:50:21 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956827, encodeId=a37495682ea4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/201a0bf1c8774775920c4db17c2a4ddb/0a8d2c62e4cb4d58b3ecbc9c2ed8b2f9.jpg, createdBy=62f95139558, createdName=1931, createdTime=Wed Apr 14 10:13:46 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087812, encodeId=edcf208e8123a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 18 12:50:21 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814540, encodeId=9f8118145402c, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Nov 25 12:50:21 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895031, encodeId=4dac89503195, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Wed Oct 28 11:45:03 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894218, encodeId=26f2894218d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:47:10 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894217, encodeId=b25a89421e0a, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:46:46 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352871, encodeId=c80713528e1dd, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555778, encodeId=e4691555e7825, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
  6. [GetPortalCommentsPageByObjectIdResponse(id=1884746, encodeId=4cb61884e46b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 21 22:50:21 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909463, encodeId=b17119094636b, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Mar 14 11:50:21 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956827, encodeId=a37495682ea4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/201a0bf1c8774775920c4db17c2a4ddb/0a8d2c62e4cb4d58b3ecbc9c2ed8b2f9.jpg, createdBy=62f95139558, createdName=1931, createdTime=Wed Apr 14 10:13:46 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087812, encodeId=edcf208e8123a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 18 12:50:21 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814540, encodeId=9f8118145402c, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Nov 25 12:50:21 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895031, encodeId=4dac89503195, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Wed Oct 28 11:45:03 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894218, encodeId=26f2894218d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:47:10 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894217, encodeId=b25a89421e0a, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:46:46 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352871, encodeId=c80713528e1dd, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555778, encodeId=e4691555e7825, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-10-28 146475c0m26(暂无昵称)

    学习了

    0

  7. [GetPortalCommentsPageByObjectIdResponse(id=1884746, encodeId=4cb61884e46b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 21 22:50:21 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909463, encodeId=b17119094636b, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Mar 14 11:50:21 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956827, encodeId=a37495682ea4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/201a0bf1c8774775920c4db17c2a4ddb/0a8d2c62e4cb4d58b3ecbc9c2ed8b2f9.jpg, createdBy=62f95139558, createdName=1931, createdTime=Wed Apr 14 10:13:46 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087812, encodeId=edcf208e8123a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 18 12:50:21 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814540, encodeId=9f8118145402c, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Nov 25 12:50:21 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895031, encodeId=4dac89503195, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Wed Oct 28 11:45:03 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894218, encodeId=26f2894218d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:47:10 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894217, encodeId=b25a89421e0a, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:46:46 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352871, encodeId=c80713528e1dd, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555778, encodeId=e4691555e7825, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-10-24 1e13341am66(暂无匿称)

    学习了

    0

  8. [GetPortalCommentsPageByObjectIdResponse(id=1884746, encodeId=4cb61884e46b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 21 22:50:21 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909463, encodeId=b17119094636b, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Mar 14 11:50:21 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956827, encodeId=a37495682ea4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/201a0bf1c8774775920c4db17c2a4ddb/0a8d2c62e4cb4d58b3ecbc9c2ed8b2f9.jpg, createdBy=62f95139558, createdName=1931, createdTime=Wed Apr 14 10:13:46 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087812, encodeId=edcf208e8123a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 18 12:50:21 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814540, encodeId=9f8118145402c, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Nov 25 12:50:21 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895031, encodeId=4dac89503195, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Wed Oct 28 11:45:03 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894218, encodeId=26f2894218d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:47:10 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894217, encodeId=b25a89421e0a, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:46:46 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352871, encodeId=c80713528e1dd, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555778, encodeId=e4691555e7825, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-10-24 1e13341am66(暂无匿称)

    厉害了

    0

  9. [GetPortalCommentsPageByObjectIdResponse(id=1884746, encodeId=4cb61884e46b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 21 22:50:21 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909463, encodeId=b17119094636b, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Mar 14 11:50:21 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956827, encodeId=a37495682ea4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/201a0bf1c8774775920c4db17c2a4ddb/0a8d2c62e4cb4d58b3ecbc9c2ed8b2f9.jpg, createdBy=62f95139558, createdName=1931, createdTime=Wed Apr 14 10:13:46 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087812, encodeId=edcf208e8123a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 18 12:50:21 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814540, encodeId=9f8118145402c, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Nov 25 12:50:21 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895031, encodeId=4dac89503195, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Wed Oct 28 11:45:03 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894218, encodeId=26f2894218d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:47:10 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894217, encodeId=b25a89421e0a, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:46:46 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352871, encodeId=c80713528e1dd, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555778, encodeId=e4691555e7825, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]
    2020-10-24 zhaojie88
  10. [GetPortalCommentsPageByObjectIdResponse(id=1884746, encodeId=4cb61884e46b6, content=<a href='/topic/show?id=3b2112532d8' target=_blank style='color:#2F92EE;'>#Nat#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=36, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=12532, encryptionId=3b2112532d8, topicName=Nat)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=2e6f107, createdName=liye789132251, createdTime=Tue Sep 21 22:50:21 CST 2021, time=2021-09-21, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1909463, encodeId=b17119094636b, content=<a href='/topic/show?id=be1864e205a' target=_blank style='color:#2F92EE;'>#治疗靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=39, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=64720, encryptionId=be1864e205a, topicName=治疗靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=a885259, createdName=yourmama, createdTime=Sun Mar 14 11:50:21 CST 2021, time=2021-03-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=956827, encodeId=a37495682ea4, content=学习, beContent=null, objectType=article, channel=null, level=null, likeNumber=65, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201022/201a0bf1c8774775920c4db17c2a4ddb/0a8d2c62e4cb4d58b3ecbc9c2ed8b2f9.jpg, createdBy=62f95139558, createdName=1931, createdTime=Wed Apr 14 10:13:46 CST 2021, time=2021-04-14, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=2087812, encodeId=edcf208e8123a, content=<a href='/topic/show?id=490750196b' target=_blank style='color:#2F92EE;'>#COMMUN#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=28, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=5019, encryptionId=490750196b, topicName=COMMUN)], attachment=null, authenticateStatus=null, createdAvatar=https://wx.qlogo.cn/mmopen/aLGWoFXAyMbIu3qymFOyheQLjPSX3OUs5GmkyBlcCOwTPIeq3why9NGibxxUqYo6hcx8qZLHZFgNPnBK1yzWeOFpyg2OnWOt0/0, createdBy=fa4716, createdName=仁心济世, createdTime=Mon Jan 18 12:50:21 CST 2021, time=2021-01-18, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1814540, encodeId=9f8118145402c, content=<a href='/topic/show?id=f72795e80d0' target=_blank style='color:#2F92EE;'>#重大进展#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=29, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=95780, encryptionId=f72795e80d0, topicName=重大进展)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=b96f328, createdName=wwzzly, createdTime=Wed Nov 25 12:50:21 CST 2020, time=2020-11-25, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=895031, encodeId=4dac89503195, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=84, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20201018/17516f06a53a4cf8b20993210840c5dd/8e57a4d799a845b9bc3fc17cb994a39c.jpg, createdBy=db415126199, createdName=146475c0m26(暂无昵称), createdTime=Wed Oct 28 11:45:03 CST 2020, time=2020-10-28, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894218, encodeId=26f2894218d6, content=学习了, beContent=null, objectType=article, channel=null, level=null, likeNumber=81, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:47:10 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=894217, encodeId=b25a89421e0a, content=厉害了, beContent=null, objectType=article, channel=null, level=null, likeNumber=87, replyNumber=0, topicName=null, topicId=null, topicList=[], attachment=null, authenticateStatus=null, createdAvatar=https://img.medsci.cn/20210311/2a8273a0f8d34d10baae98ab03ee8bdc/083e1bc82d3a438891b1052e1192a529.jpg, createdBy=fd361960002, createdName=1e13341am66(暂无匿称), createdTime=Sat Oct 24 23:46:46 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1352871, encodeId=c80713528e1dd, content=<a href='/topic/show?id=827d9996311' target=_blank style='color:#2F92EE;'>#靶标#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=26, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=99963, encryptionId=827d9996311, topicName=靶标)], attachment=null, authenticateStatus=null, createdAvatar=, createdBy=4c37265, createdName=zhaojie88, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=), GetPortalCommentsPageByObjectIdResponse(id=1555778, encodeId=e4691555e7825, content=<a href='/topic/show?id=5900221140f' target=_blank style='color:#2F92EE;'>#中山大学#</a>, beContent=null, objectType=article, channel=null, level=null, likeNumber=32, replyNumber=0, topicName=null, topicId=null, topicList=[TopicDto(id=22114, encryptionId=5900221140f, topicName=中山大学)], attachment=null, authenticateStatus=null, createdAvatar=null, createdBy=0d5414663053, createdName=kalseyzl, createdTime=Sat Oct 24 13:50:21 CST 2020, time=2020-10-24, status=1, ipAttribution=)]

相关资讯

Science:科学家首次在体外重建HIV复制和整合过程,病毒“保护壳”或是治疗突破口

人类免疫缺陷病毒(HIV),即艾滋病(AIDS)病毒,是造成人类免疫系统缺陷的一种病毒。当前,抗逆转录病毒疗法(ART)通过阻断病毒酶作用达到抑制病毒复制的效果,为HIV感染者赢得一线生机。

Nat Biomed Eng :单碱基编辑首次在治疗遗传性眼病上取得成功,安全高效治疗先天性黑蒙症

先天性黑蒙症(LCA)是一类因影响视网膜功能的几个重要基因的功能丧失突变引起的遗传性视网膜疾病,主要为常染色体隐性遗传。大多数LCA患者在婴儿期或儿童期就开始出现严重的视力障碍。

JCEM:妊娠糖尿病治疗与子女儿童期成长的关系

尽管在出生时检测了生长差异,但研究人员观察到治疗组(包括使用格列本脲治疗的GDM妇女的子女)在6个月至3岁的童年生长方面没有显著差异。

Nat Biomed Eng:**“打击”白血病!中国科学家开发出新型治疗性白血病疫苗

作为血液系统恶性肿瘤之一,白血病严重威胁了人类的健康。虽然常规化学疗法取得了进步,但许多患者仍然面临棘手的问题,包括严重的毒性反应和对化学疗法的不敏感性。最近,免疫疗法已成为治疗白血病的新突破。

PNAS:细胞膜纳米囊泡,缓解新冠肺炎的新疗法

由新冠病毒SARS-CoV-2引起的COVID-19新冠肺炎大流行,给人类的医疗、经济、生活带来了巨大的负面影响。如何快速应对正在发生的COVID-19新冠肺炎以及潜在的新发流行疾病?

Science:发现一种罕见的痴呆症基因,为治疗阿尔兹海默症等疾病开辟新道路

阿尔茨海默症(Alzheimer's disease, AD),俗称“老年痴呆症”,是一类主要发生于老年人且以进行性认知功能障碍和行为损害为特征的中枢神经系统退行性病变。